Development of taste-masking microcapsules containing azithromycin by fluid bed coating for powder for suspension and in vivo evaluation
This research aims to develop bitter taste-masking microcapsules containing azithromycin (AZI) by a simpler and familiar method, fluid-bed coating technology, in comparison with Zithromax®. Cores of microcapsules, AZI microparticles, were prepared by fluid-bed granulation, then taste-masking polymer was covered on by fluid-bed coating technique. Eudragit L100, Eudragit RL100, and ethyl cellulose in single and combined with Eudragit L100 and Eudragit E100 were used as taste-masking polymers. The obtained microcapsules were characterised by taste-masking ability, in vitro release, SEM, coating thickness, and coating efficiency. Combination of ethyl cellulose and Eudragit E100 (3:1) in coating thickness of 45.13 ± 2.12% w/w prevents AZI release from microcapsules below bitter taste threshold (1.78 ± 1.17 µg/ml). Bioavailability of powders containing AZI microcapsules and pH modulators (50 mg Na3PO4 and 35 mg Mg(OH)2) was not significantly different from the reference product (Zithromax®, Pfizer, New York, NY) in the rabbit model (p > 0.05). These results support the possibility of developing a generic product containing AZI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 40(2023), 5 vom: 17. Dez., Seite 345-356 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dung, Pham-Thi-Phuong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.07.2023 Date Revised 18.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2023.2209639 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356331873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356331873 | ||
| 003 | DE-627 | ||
| 005 | 20231226070231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2023.2209639 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356331873 | ||
| 035 | |a (NLM)37129865 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dung, Pham-Thi-Phuong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of taste-masking microcapsules containing azithromycin by fluid bed coating for powder for suspension and in vivo evaluation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This research aims to develop bitter taste-masking microcapsules containing azithromycin (AZI) by a simpler and familiar method, fluid-bed coating technology, in comparison with Zithromax®. Cores of microcapsules, AZI microparticles, were prepared by fluid-bed granulation, then taste-masking polymer was covered on by fluid-bed coating technique. Eudragit L100, Eudragit RL100, and ethyl cellulose in single and combined with Eudragit L100 and Eudragit E100 were used as taste-masking polymers. The obtained microcapsules were characterised by taste-masking ability, in vitro release, SEM, coating thickness, and coating efficiency. Combination of ethyl cellulose and Eudragit E100 (3:1) in coating thickness of 45.13 ± 2.12% w/w prevents AZI release from microcapsules below bitter taste threshold (1.78 ± 1.17 µg/ml). Bioavailability of powders containing AZI microcapsules and pH modulators (50 mg Na3PO4 and 35 mg Mg(OH)2) was not significantly different from the reference product (Zithromax®, Pfizer, New York, NY) in the rabbit model (p > 0.05). These results support the possibility of developing a generic product containing AZI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Azithromycin | |
| 650 | 4 | |a Eudragit L100 | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a bitter taste masking | |
| 650 | 4 | |a ethyl cellulose | |
| 650 | 4 | |a microcapsule | |
| 650 | 4 | |a pH modulator | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a methylmethacrylate-methacrylic acid copolymer |2 NLM | |
| 650 | 7 | |a 25086-15-1 |2 NLM | |
| 650 | 7 | |a Eudragit E100 |2 NLM | |
| 650 | 7 | |a Powders |2 NLM | |
| 650 | 7 | |a Capsules |2 NLM | |
| 700 | 1 | |a Trinh, Thanh-Dat |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Quoc-Hoai |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Huu-Manh |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Ngoc-Chien |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Ngoc-Bao |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Cao-Son |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Thi-Hong-Ngoc |e verfasserin |4 aut | |
| 700 | 1 | |a Tung, Nguyen-Thach |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 40(2023), 5 vom: 17. Dez., Seite 345-356 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:5 |g day:17 |g month:12 |g pages:345-356 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2023.2209639 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 5 |b 17 |c 12 |h 345-356 | ||